Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

NCT01652729 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01652729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01652729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
April 30, 2014
Enrollment
365 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 2